Genprex, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for GNPX, updated each market day.
GNPX AI Sentiment
AI predicts Genprex, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Genprex, Inc. Common Stock
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Sector
Exchange
Market Cap
$11,758,312
Cap Tier
Employees
13
Headquarters
AUSTIN, TX
Listed Since
March 29, 2018
Website
GNPX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GNPX Volatility
Genprex, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
